Curated News
By: NewsRamp Editorial Staff
April 29, 2026

Silo Pharma Hails U.S. Federal Push for Psychedelic Therapies

View History of this news story on GitHub
Original Source

TLDR

  • Silo Pharma gains an edge as federal actions accelerate psychedelic therapy development, driving innovation in PTSD and addiction treatments.
  • ARPA-H and FDA initiatives, including IND clearance for noribogaine and priority vouchers, are advancing psychedelic therapies through clearer regulatory pathways.
  • U.S. federal support for psychedelic therapies promises better treatments for mental health and addiction, improving countless lives.
  • Silo Pharma highlights noribogaine IND clearance and priority vouchers as key signals of growing institutional support for psychedelic research.

Impact - Why it Matters

This news matters because it signals a paradigm shift in mental health treatment, with federal agencies actively supporting psychedelic-based therapies. For patients suffering from PTSD, addiction, and other conditions, this could mean access to novel, effective treatments sooner. Investors should note the growing legitimacy and potential for significant returns as regulatory pathways clear.

Summary

Silo Pharma (NASDAQ: SILO) has weighed in on a series of coordinated U.S. federal actions that are accelerating the development of psychedelic-based therapies for mental health and substance use disorders. The company highlighted new funding initiatives, clinical progress, and regulatory advancements from agencies such as ARPA-H and the FDA. Notable developments include the IND clearance for a noribogaine candidate and the issuance of priority vouchers to leading organizations. These signals of growing institutional support and increased clarity are expected to drive innovation in treating conditions like PTSD and addiction.

Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio features innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories, as detailed on their website silopharma.com.

The news was disseminated by PsychedelicNewsWire ("PNW"), a specialized communications platform focusing on the psychedelics sector. PNW is part of the Dynamic Brand Portfolio @ IBN, which offers a range of services including press release distribution via InvestorWire, editorial syndication to over 5,000 outlets, and social media distribution. For more information, visit PsychedelicNewsWire. To receive SMS alerts, text "Groovy" to 888-902-4192 (U.S. Mobile Phones Only). The full press release can be accessed at https://ibn.fm/TpB23.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Silo Pharma Hails U.S. Federal Push for Psychedelic Therapies

blockchain registration record for this content.